JP2024531900A5 - - Google Patents

Info

Publication number
JP2024531900A5
JP2024531900A5 JP2024505469A JP2024505469A JP2024531900A5 JP 2024531900 A5 JP2024531900 A5 JP 2024531900A5 JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024531900 A5 JP2024531900 A5 JP 2024531900A5
Authority
JP
Japan
Application number
JP2024505469A
Other languages
Japanese (ja)
Other versions
JPWO2023010100A5 (https=
JP2024531900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074286 external-priority patent/WO2023010100A1/en
Publication of JP2024531900A publication Critical patent/JP2024531900A/ja
Publication of JP2024531900A5 publication Critical patent/JP2024531900A5/ja
Publication of JPWO2023010100A5 publication Critical patent/JPWO2023010100A5/ja
Pending legal-status Critical Current

Links

JP2024505469A 2021-07-28 2022-07-28 新規の抗sirpa抗体 Pending JP2024531900A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/109041 2021-07-28
CN2021109041 2021-07-28
CNPCT/CN2022/104562 2022-07-08
CN2022104562 2022-07-08
PCT/US2022/074286 WO2023010100A1 (en) 2021-07-28 2022-07-28 Novel anti-sirpa antibodies

Publications (3)

Publication Number Publication Date
JP2024531900A JP2024531900A (ja) 2024-09-03
JP2024531900A5 true JP2024531900A5 (https=) 2025-08-04
JPWO2023010100A5 JPWO2023010100A5 (https=) 2025-08-04

Family

ID=85087323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505469A Pending JP2024531900A (ja) 2021-07-28 2022-07-28 新規の抗sirpa抗体

Country Status (9)

Country Link
US (1) US20250270315A1 (https=)
EP (1) EP4377358A4 (https=)
JP (1) JP2024531900A (https=)
KR (1) KR20240039006A (https=)
CN (1) CN118076638A (https=)
AU (1) AU2022317822A1 (https=)
CA (1) CA3227854A1 (https=)
TW (1) TW202313699A (https=)
WO (1) WO2023010100A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120569409A (zh) * 2023-01-18 2025-08-29 科望(苏州)生物医药科技有限公司 靶向sirpa和claudin 18.2的双特异性分子
EP4702053A1 (en) * 2023-04-27 2026-03-04 LaNova Medicines Limited Combination treatment targeting sirpa and claudin 18.2
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
KR20250079073A (ko) * 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
JP7437815B2 (ja) * 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗SIRPαモノクローナル抗体およびその使用

Similar Documents

Publication Publication Date Title
JP2024531900A5 (https=)
JP2024527043A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022000931U2 (https=)
BY13169U (https=)
BY13162U (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13153U (https=)
BY13168U (https=)